文献速递主动脉疾病

25例Ⅰ型内漏经导管栓塞术后早中期结局

Early and midterm outcomes after transcatheter embolization of type I endoleaks in 25 patients.
PubMed 文献 · J Vasc Surg · 2017-01-01

本研究回顾25例腹主动脉腔内修复(EVAR)后Ⅰ型内漏患者,因不适合标准腔内方法而接受经导管栓塞(单纯Onyx或联合可脱弹簧圈)。全部手术即时技术成功,随访平均311天,内漏复发率28%,无内漏复发率80%、无瘤囊增长率85%。作者认为该法安全可行且疗效可持续。

要点

  • 全部27例次栓塞术即时技术成功,完成造影内漏完全隔绝。
  • 随访平均311天,7例(28%)内漏复发,4例持续内漏中3例死于瘤囊破裂。
  • Onyx注射前追加弹簧圈栓塞可能带来更好结局。

核心结论

  • 对不适合标准腔内方法治疗的EVAR后Ⅰ型内漏患者,经导管栓塞是安全、可行且可持续的治疗选择。
  • Onyx注射前追加弹簧圈栓塞可能获得更好结果。

研究设计与样本

  • 单中心回顾性病例系列,纳入25例EVAR后Ⅰ型内漏患者(20男、5女,平均年龄80岁,范围64-96岁)。
  • 23例近端、2例远端内漏,均不适合标准腔内方法;共行27次栓塞术,2例接受重复手术。

主要发现

  • 栓塞前平均瘤囊直径8.2 cm(范围5.3-12.9 cm);EVAR至诊断内漏平均685天(范围1-4220天),诊断至栓塞平均27天(范围2-94天)。
  • 16例单纯使用Onyx,11例Onyx联合弹簧圈;全部手术即时技术成功。
  • 6例次操作并发症:3例穿刺点血肿、3例Onyx非靶向栓塞,均无长期后遗症。
  • 随访平均311天(范围1-1357天),7例(28%)内漏复发;平均随访311天时无内漏复发率80%、无瘤囊增长率85%。
  • 复发病例中2例再次栓塞(1例无复发、1例复发后死于瘤囊破裂);另5例中2例经其他方法成功处理、1例置入主动脉延长段后内漏持续、2例不适合进一步干预。

临床怎么用

  • 对EVAR后Ⅰ型内漏且不适合标准腔内修复者,可考虑经导管Onyx栓塞(可联合可脱弹簧圈)。
  • 术后需密切随访内漏复发与瘤囊变化,持续内漏者瘤囊破裂风险高。

局限性

  • 单中心小样本回顾性病例系列(25例),随访时间有限(平均311天),缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study reports the technical success and follow-up results of transcatheter embolization of type I endoleak (ELI) in 25 patients after endovascular aortic repair (EVAR). METHODS: Twenty-five patients with ELI (20 men, five women; mean age 80 years; range, 64-96 years) underwent embolization of abdominal ELI (23 proximal, 2 distal endoleaks) after EVAR. All patients were unsuitable for standard endovascular methods for treatment of ELI. The average aneurysm sac size before embolization was 8.2 cm (range, 5.3-12.9 cm). The average time between EVAR and endoleak diagnosis was 685 days (range, 1-4220 days) and from endoleak diagnosis to embolization was 27 days (range, 2-94 days). Onyx (ev3 Endovascular, Inc, Plymouth, Minn) alone or with detachable coils was used for embolization. RESULTS: A total of 27 embolization procedures were performed, with two patients having undergone a repeat procedure. Onyx alone was used in 16 cases and Onyx and coils were used in 11. Immediate technical success with complete isolation of the endoleak on completion angiography was achieved in all procedures. Six procedural complications occurred: three puncture site hematomas and three cases of non-target Onyx embolization. None of the complications had long term sequelae. During the follow-up period (average, 311 days; range, 1-1357 days), seven patients (28%) developed endoleak recurrence, and two underwent a second embolization procedure. Of these, one has had no further endoleak recurrence, but the other developed a recurrent endoleak and died of sac rupture. Two of the other five cases of endoleak recurrence were successfully managed by other procedures, one had a persistent endoleak despite aortic cuff placement, and the other two were deemed unsuitable for further intervention. Three of the four patients with persistent endoleaks died of sac rupture. At the average follow-up time of 311 days, freedom from endoleak recurrence was 80%, and freedom from sac growth was 85%. CONCLUSIONS: Transcatheter embolization of ELI offers a safe, feasible, and sustainable treatment option for patients who are unsuitable for standard methods of ELI treatment. Additional coil embolization before Onyx injection may result in better outcome.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Ameli-Renani S, Pavlidis V, Morgan RA, et al. Early and midterm outcomes after transcatheter embolization of type I endoleaks in 25 patients. J Vasc Surg. 2017. PMID: 28126173. doi:10.1016/j.jvs.2016.06.101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。